Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Ikena, Senti and others look to clinical presentations at AACR.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
The company is stepping back in second-line breast cancer.
